Bio Pharma Dive
APRIL 10, 2022
The slowdown has already forced many biotechs to wait longer to go public. There are early signs private financing deals may be flagging as well.
Scienmag
APRIL 10, 2022
A trial in which trainee teachers who were being taught to identify pupils with potential learning difficulties had their work ‘marked’ by artificial intelligence has found the approach significantly improved their reasoning. Credit: Credit: Michael Sailer, LMU-Munich A trial in which trainee teachers who were being taught to identify pupils with potential learning difficulties had […].
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
JAMA Internal Medicine
APRIL 10, 2022
This survey study assesses vaccination intentions of unvaccinated US adults in response to full US Food and Drug Administration (FDA) approval of the BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine and any demographic characteristics associated with those intentions.
Scienmag
APRIL 10, 2022
A new study found that older children and those with high blood markers for inflammation (ferritin) were at highest risk of severe multisystem inflammatory syndrome in children (MIS-C) and admission to the intensive care unit (ICU). The research is published in CMAJ (Canadian Medical Association Journal) [link] The international study included 232 children younger than 18 admitted […].
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Drug Patent Watch
APRIL 10, 2022
Annual Drug Patent Expirations for TEFLARO Teflaro is a drug marketed by Allergan and is included in one NDA. It is available from one supplier. There are three patents protecting…. The post New patent expiration for Allergan drug TEFLARO appeared first on DrugPatentWatch - Make Better Decisions.
Scienmag
APRIL 10, 2022
Niigata, Japan – Superconductor will play a huge role in emerging technologies. Hence, it is critical to understand the physics fundamentally. Although the mechanisms of “high-Tc” cuprate superconductors are unknown, the CuO2 planes are generally believed to be the driving force of superconductivity (SC). This is because all the “high-Tc” cuprate superconductors have CuO2 planes.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Scienmag
APRIL 10, 2022
Abstract: CT003 Researchers from The University of Texas MD Anderson Cancer Center showed that natural killer (NK) cells derived from donated umbilical cord blood, combined with a novel bispecific antibody known as AFM13 that targets CD16A and CD30, achieved effective responses in patients with pretreated and refractory CD30+ lymphoma. The study was presented today at […].
Drug Patent Watch
APRIL 10, 2022
Annual Drug Patent Expirations for SPIRIVA Spiriva is a drug marketed by Boehringer Ingelheim and is included in two NDAs. It is available from two suppliers. There are sixteen patents…. The post New patent expiration for Boehringer Ingelheim drug SPIRIVA appeared first on DrugPatentWatch - Make Better Decisions.
Scienmag
APRIL 10, 2022
Depending on where some people live in the UK could mean they are denied an NHS treatment which helps patients with medical needs, such as cancer and transgender issues, become parents in the future. That’s according to a new study, which audited UK healthcare commissioner fertility preservation policies, to find that funding across the NHS […].
pharmaphorum
APRIL 10, 2022
A US jury has decided that Daiichi Sankyo and AstraZeneca’s breast cancer drug Enhertu infringes a patent held by US biotech Seagen, awarding almost $42 million in damages. Seagen claims Enhertu (trastuzumab deruxtecan) – an antibody-drug conjugate (ADC) targeting HER2 – infringes a patient it holds (No. 10,808,039) covering ADCs that include auristatin compounds coupled to an antibody via a linker molecule.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Scienmag
APRIL 10, 2022
NEW ORLEANS – More than 10 percent of cases of recurrent ductal carcinoma in situ (DCIS) of the breast were “de novo” tumors that occurred independently of the primary lesion and had distinct genetic alterations, according to data presented during the AACR Annual Meeting 2022, held April 8-13. “DCIS is a precancerous lesion that recurs […].
Drug Patent Watch
APRIL 10, 2022
This chart shows the pharmaceutical companies with the most ointment dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most ointment dosed drugs…. The post Which pharmaceutical companies have the most ointment dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.
Scienmag
APRIL 10, 2022
NEW ORLEANS – Patients with non-small cell lung cancer (NSCLC) treated with the KRAS G12C inhibitor sotorasib (Lumakras) had a two-year overall survival rate of 32.5 percent, according to data from the CodeBreaK 100 clinical trial presented during the AACR Annual Meeting 2022, held April 8-13. Based on the primary analysis from this trial, the […].
The Pharma Data
APRIL 10, 2022
Long-Term Clinical Benefit and Prolonged Tumor Response Seen With 40.7% Objective Response Rate. No New Safety Signals Observed. Longest Follow-Up of Patients Treated With a KRAS G12C Inhibitor. Amgen (NASDAQ: AMGN) today announced the presentation of long-term efficacy and safety data from the CodeBreaK 100 Phase 1/2 trial in patients with KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC) who received LUMAKRAS® (sotorasib)*.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Scienmag
APRIL 10, 2022
NEW ORLEANS – A variant of the CTLA-4 gene associated with autoimmune disease was found to be more frequent in non-small cell lung cancer (NSCLC) patients who experienced an exceptionally high response to anti-PD-1 immunotherapy and higher immune-related side effects than in a comparable cohort of lung cancer patients and healthy individuals, according to data […].
Scienmag
APRIL 10, 2022
NEW ORLEANS ? Results from early-stage clinical trials show two drugs that target the DNA damage response (DDR) pathway in cancers — ATR inhibitor elimusertib and PARP inhibitor AZD5305 — are safe and clinically beneficial in treating patients with advanced solid tumors. Principal investigator Timothy Yap, M.B.B.S., Ph.D., associate professor of Investigational Cancer Therapeutics, today […].
Expert insights. Personalized for you.
337 
Let's personalize your content